U.S. markets open in 9 hours 21 minutes
  • S&P Futures

    3,837.75
    +28.50 (+0.75%)
     
  • Dow Futures

    31,106.00
    +194.00 (+0.63%)
     
  • Nasdaq Futures

    13,042.00
    +131.00 (+1.01%)
     
  • Russell 2000 Futures

    2,232.40
    +33.20 (+1.51%)
     
  • Crude Oil

    62.42
    +0.92 (+1.50%)
     
  • Gold

    1,747.80
    +19.00 (+1.10%)
     
  • Silver

    26.95
    +0.51 (+1.93%)
     
  • EUR/USD

    1.2083
    -0.0004 (-0.04%)
     
  • 10-Yr Bond

    1.4600
    -0.0580 (-3.82%)
     
  • Vix

    27.95
    -0.94 (-3.25%)
     
  • GBP/USD

    1.3971
    +0.0049 (+0.35%)
     
  • USD/JPY

    106.4700
    -0.0320 (-0.03%)
     
  • BTC-USD

    46,446.57
    +1,864.63 (+4.18%)
     
  • CMC Crypto 200

    928.49
    -4.65 (-0.50%)
     
  • FTSE 100

    6,483.43
    -168.53 (-2.53%)
     
  • Nikkei 225

    29,570.67
    +604.66 (+2.09%)
     

Recap: Inspire Medical Systems Q4 Earnings

  • Oops!
    Something went wrong.
    Please try again later.
Benzinga Insights
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

Shares of Inspire Medical Systems (NYSE:INSP) rose in after-market trading after the company reported Q4 results.

Quarterly Results

Earnings per share were up 26.32% over the past year to ($0.28), which beat the estimate of ($0.48).

Revenue of $46,009,000 up by 71.00% from the same period last year, which beat the estimate of $41,070,000.

Outlook

Inspire Medical Sees FY21 Sales $183M-$188M vs $171.7M Estimate

Details Of The Call

Date: Feb 23, 2021

Time: 05:00 PM

View more earnings on INSP

ET Webcast URL: http://public.viavid.com/player/index.php?id=143162

Technicals

52-week high: $239.40

Company's 52-week low was at $40.53

Price action over last quarter: Up 39.33%

Company Overview

Inspire Medical Systems Inc operates as a medical technology company. It focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The firm has operating footprints in the United States and Europe wherein, it generates a majority of its revenue from the United States.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.